Results 101 to 110 of about 22,482 (226)

Intravitreal aflibercept for choroidal neovascularization associated with chorioretinitis: a pilot study

, 2017
Andrii R Korol,1 Oleksandra Zborovska,2 Taras Kustryn,1 Oleksandra Dorokhova,2 Nataliya Pasyechnikova3 1Laser Department, 2Department of Inflammatory Pathology of the Eye, 3Filatov Institute of Eye Diseases and Tissue Therapy, National Academy
Kustryn T, Korol AR, Zborovska O, Dorokhova O, Pasyechnikova N   +4 more
core  

Viability of Primary Human Pigment Epithelium Cells and Muller-Glia Cells after Intravitreal Ziv-Aflibercept and Aflibercept [PDF]

, 2016
Purpose: The aim of this study was to access the safety profiles of 2 fusion proteins with anti-vascular endothelial growth factor action (ziv-aflibercept and aflibercept) on retinal pigment epithelium cells and Muller-Glia cells in culture by assessing ...
Haritoglou, Christos, Wolf, Armin, Eibl, Kirsten, Rodrigues, Eduardo Buchele, Farah, Michel Eid [UNIFESP], de Andrade, Gabriel Costa [UNIFESP], Costa de Andrade, G., Wertheimer, Christian, Eibl, Kirsten H., Haritoglou, Christos [UNIFESP], Farah, Michel Eid, Rodrigues, Eduardo Buchele [UNIFESP], Kampik, Anselm   +12 more
core   +1 more source

Injection burden and treatment intervals of aflibercept in observe‐and‐plan regimen for neovascular age‐related macular degeneration

Acta ophthalmologica
The Observe‐and‐Plan (O&P) regimen allows for individualised treatment. In this study, we evaluated injection burden and intervals using aflibercept in an O&P regimen for eyes with neovascular age‐related macular degeneration (AMD).
Y. Subhi, Miklos Schneider, J. Hajari, M. la Cour   +3 more
semanticscholar   +1 more source

Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema

, 2017
Sameh Mosaad Fouda, Ahmed M Bahgat Department of Ophthalmology, Faculty of Medicine, Zagazig University, Zagazig, Egypt Purpose: The purpose of this study was to compare the efficacy of intravitreal aflibercept and ranibizumab in the treatment of ...
Bahgat AM, Fouda SM
core  

Evaluation of Aflibercept Treatment Responses in Eyes with Bevacizumab/Ranibizumab-resistant Wet Age-related Macular Degeneration

, 2017
Objectives: To evaluate anatomic and functional results after switching from intravitreal bevacizumab or ranibizumab treatment to aflibercept for wet (neovascular) age-related macular degeneration.
Abdullah Kaya, Ali Ayata, Cihan Büyükavşar, Tuncay Topal, Sercan Koray Sağdıç, Taner Kar, Melih Hamdi Ünal, Murat Sönmez, Yıldıray Yıldırım   +8 more
core   +1 more source

Clinical experience with fixed bimonthly aflibercept dosing in treatment-experienced patients with neovascular age-related macular degeneration

, 2015
Arshad M Khanani Sierra Eye Associates, Reno, NV, USA Purpose: To evaluate the durability of fixed bimonthly dosing of intravitreal aflibercept for neovascular age-related macular degeneration.Methods: Records of 16 patients were retrospectively ...
Khanani AM
core  

One-Month Real-World Comparison of Aflibercept 8 mg Versus 2 mg in Treatment-Naïve and Previously Treated Eyes with Neovascular Age-Related Macular Degeneration

Biologics
Background/Objectives: The relative efficacy of 8 mg aflibercept compared to 2 mg in treating neovascular age-related macular degeneration (nAMD) has not been fully established. This study aims to compare the visual and anatomical outcomes of aflibercept
Takahiro Mizukami, Satoru Ueno, Soichiro Mishima, Yoshikazu Shimomura   +3 more
doaj   +1 more source

Switch to faricimab after initial treatment with aflibercept in eyes with neovascular age-related macular degeneration

International ophtalmology
To investigate the efficacy and outcomes of switching neovascular age-related macular degeneration (nAMD) patients from aflibercept to faricimab, focusing on visual acuity, retinal fluid management, and treatment intervals.
Aisha A. Aldhanhani, O. Azzam, Sahar H. AlAli, Khaled G. Almasri, Shaikha Aljneibi, Francesco Pichi   +5 more
semanticscholar   +1 more source

Switching to Faricimab or High‐Dose Aflibercept for Neovascular AMD in High‐Demand Patients: Impact on Injection Interval in a Real‐World Cohort

Clinical &Experimental Ophthalmology, Volume 54, Issue 5, Page 724-726, July 2026.
Zachary George Angus, Yin‐Zhi Lee, Sukhpal Singh Sandhu, Robyn Troutbeck, Jonathan Yeoh, Daniel Chiu, Manishka Jayasundera, Jaesser Tan, Sanjeewa Wickremasinghe   +8 more
wiley   +1 more source

Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture [PDF]

, 2014
PurposeTo compare the safety profiles of antivascular endothelial growth factor (VEGF) drugs ranibizumab, bevacizumab, aflibercept and ziv-aflibercept on retinal pigment epithelium cells in culture.MethodsHuman retinal pigment epithelium cells (ARPE-19 ...
Kuppermann, Baruch D, del Carpio, Javier Caceres, Kenney, M Cristina, Boyer, David, Malik, Deepika, Tarek, Mohamed, Ramirez, Claudio   +6 more
core   +1 more source